Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company focused on developing gene therapies for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease. Founded in 2018, it aims to treat the root causes of these conditions using advanced, data-driven approaches derived from research at Weill Cornell Medicine and UC San Diego.